Sentiment · ELV

Lobbying Spend for ELV

AI-generated plain-English read of lobbying spend for ELV. Updated daily.

Heavy lobbying, trending higher

high

Heavy and rising. The company is building a more serious DC presence quarter over quarter — watch for a policy catalyst that would explain the ramp.

What will probably happen

  • A rising trend without an obvious single catalyst suggests broadening DC engagement — a structural shift, not a one-quarter reaction.
  • Spend is spread across many issue areas — the company has diverse regulatory exposure and is fighting on multiple fronts simultaneously.

What to do

If you HOLD this stock
Deepening DC engagement — hold your position but monitor the primary issue area for policy news that could catalyze a move in either direction.
If you're EVALUATING this stock
Heavy DC presence is a recurring cost and risk factor — factor in the regulatory environment when sizing. Requires research into the primary issue areas.
If you trade OPTIONS
No clean options signal derived from this lobbying read.

13 quarters of history with $31.43M in total spend — sufficient data for a reliable trajectory read.

Technical details

Technical analysis

Spend tier
Heavy
Trajectory
Rising
Last quarter
$1.86M
Last 4Q total
$10.91M
Prior 4Q total
$9.81M
Top issue area
HEALTH ISSUES (56% of spend)
Top registrant
ELEVANCE HEALTH, INC. (83% of spend)
Registrant base
In house
Quarters on record
13
Unique issue areas
9
Unique registrants
11
Issue concentration
Broad

Key levels

Key price and metric levels
LevelValue
total amount31,430,000
last 4q total10,915,000
top issue pct0.563
prior 4q total9,810,000
top registrant pct0.831
last quarter amount1,865,000

Caveats

  • Lobbying disclosures are quarterly and reflect activity already past. The signal is structural, not timing.
  • The primary registrant appears to be an in-house government-affairs operation. In-house lobbying may not be captured in full by third-party disclosure data.

More Sentiment reads for ELV

For informational and educational purposes only. Not financial advice. Learn more